cas 154057-58-6, [2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium bromido

Articles about 154057-58-6Total 9 be found

A novel preparation method of a pitavastatin calcium intermediate
The invention relates to a preparation method of [[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]methyl]triphenylphosphonium bromide, comprising the following steps: reacting 2-Cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-methanol and triphenylphosphine hydrobromide in an organic solvent to obtain a target compound. The preparation method provided by the invention has the advantages of easily available raw materials, simple operation and high yield, effectively reduces phosphorus-containing wastewater and phosphorus-containing waste residues, reduces the production cost, and is beneficial to large-scale production.
-
Paragraph 0021-0032

(2019/07/11)

The use of a lactonized statin side-chain precursor in a concise and efficient assembly of pitavastatin
A concise and simple synthetic route to pitavastatin is described. The approach involves a highly stereoselective Wittig olefination reaction between a lactonized statin side-chain precursor and the triphenylphosphonium bromide salt of the corresponding quinoline heterocyclic core. The necessary O-tert-butyl(dimethyl)silyl-protected pitavastatin lactone was obtained in 75% yield and high purity by simple crystallization from aqueous methanol. Subsequent deprotection, hydrolysis, and cation exchange in a one-pot operation provided pitavastatin calcium in 93% yield. Georg Thieme Verlag Stuttgart · New York.
Fabris, Jan,Casar, Zdenko,Smilovic, Ivanagazi
experimental part
p. 1700 - 1710
(2012/07/27)

METHOD FOR PREPARATION OF PITAVASTATIN AND ITS PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.
-
Page/Page column 9-10

(2012/02/03)

PITAVASTATIN CALCIUM AND PROCESS FOR ITS PREPARATION
The invention provides the process for the preparation of pitavastatin and its pharmaceutically acceptable salts thereof. In particular, the invention provides a process for the preparation of stable pitavastatin calcium in crystalline form having water content less than 5% wt/wt. The present invention also provides stable crystalline form of pitavastatin calcium substantially free from crystal Form-A and use thereof for pharmaceutical compositions.
-
Page/Page column 21

(2012/03/26)

NOVEL POLYMORPHS OF PITAVASTATIN CALCIUM
The present invention provides a solid of pitavastatin tert-butyl ester and process for its preparation. The present invention also provides a novel crystalline form of pitavastatin calcium, process for its preparation and pharmaceutical compositions comprising it.
-
Page/Page column 9-10

(2012/05/31)

Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof
Processes for preparing pravastatin, intermediates and pharmaceutically acceptable salts thereof are provided Crystalline forms of pravastatin, intermediates and pharmaceutically acceptable salts thereof are also disclosed.
-
(2012/02/01)

PROCESS FOR PREPARING PITAVASTATIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.
-
Page/Page column 21

(2011/08/08)

NOVEL PROCESS FOR THE PREPARATION OF PITAVASTATIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
Novel Process for the preparation of Pravastatin and its pharmaceutically acceptable salts compound of formula- 1 via novel triphenyl phosphonium bromide salt compound of formula-3 or tributyl phosphonium bromide salt compound of formula-7 by employing Wittig reagents. Formula (I): Wherein M is H, Na+,K+,Mg+2,Ca+2.
-
Page/Page column 12

(2010/11/29)

Synthesis of artificial HMG-CoA reductase inhibitors based on the olefination strategy
Synthetic methods were studied for optically active 6-oxo-3,5-isopropylidenedioxyhexanoate esters (4), which could be used as a key precursor of various kinds of artificial analogs of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. An enantiomer (+)-4 was prepared by asymmetric reduction of β,δ-diketo esters derived from the Taber's alcohol or L-tartrate followed by a series of chemical transformations, and the desired enantiomer (-)-4 was prepared by the same asymmetric reduction starting from D-tartrate. The key intermediate (-)-4 was finally converted into a highly potent HMG-CoA reductase inhibitor, NK-104.
Hiyama,Minami,Takahashi
p. 364 - 372
(2007/10/02)